Evidence map›Paper›PMID 37686514›Full record

ArticleCancers2023

Enhanced Therapeutic Effects of

Tabassom Mohajershojai, Douglas Spangler, Saloni Chopra, Fredrik Y Frejd, Paul J Yazaki, Marika Nestor

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Tabassom MohajershojaiDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-7364-5470
Douglas SpanglerDepartment of Public Health and Caring Sciences, Uppsala University, 751 22 Uppsala, Sweden.ORCID 0000-0001-6775-5051
Saloni ChopraDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Fredrik Y FrejdDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Paul J YazakiDepartment of Immunology & Theranostics, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Marika NestorDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-4662-3142
Uppsala University · SECity Of Hope National Medical Center · US

Funding

Barncancerfonden PR2020-0023, TJ2021-551 0072Stiftelsen Ulf Lundahls minnesfond PR2020-0023, TJ2021-551 0072Swedish Cancer Society CAN 21/1534, CAN 20 0191Swedish Research Council 2020-01377
6 · The paper itself

Abstract

Carcinoembryonic antigen (CEA) has emerged as an attractive target for theranostic applications in colorectal cancers (CRCs). In the present study, the humanized anti-CEA antibody hT84.66-M5A (M5A) was labeled with

Indexed as

177Lu-DOTA-M5Acarcinoembryonic antigencombination therapyHSP90 inhibitor onalespibradioimmunotherapy

Identifiers

PMID37686514
PMCPMC10486833
OpenAlexW4386134949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.